October 4, 2010
Otsuka Pharmaceutical Co., Ltd.
OTSUKA OPENS FIRST OFFICE IN CANADA
Important Milestone for Growing North American Pharmaceutical Operations
MONTREAL, CANADA and TOKYO, JAPAN, October 4th, 2010 - Otsuka Canada Pharmaceutical Inc. (OCPI) has opened its first Canadian office, in the Montreal suburb of Saint-Laurent. This marks a major milestone in the continued growth of Otsuka in North America.
OCPI will initially promote two Otsuka products: ABILIFY® (aripiprazole) and IV BUSULFEX® (busulfan) Injection. ABILIFY (aripiprazole) is indicated for the treatment of schizophrenia and related psychotic disorders and the acute treatment of manic or mixed episodes in Bipolar I Disorder. OCPI will co-promote ABILFY with Bristol-Myers Squibb Canada. IV BUSULFEX (busulfan) Injection is indicated for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation; this includes acute lymphocytic leukemia, acute non-lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, myelodysplastic syndrome and several genetic diseases.
OCPI plans to seek regulatory approval to bring additional innovative products to the Canadian market in the future.
"We are delighted to establish this permanent presence in Canada," said Masaru Taguchi, General Manager of OCPI. "We believe Otsuka has a great deal to contribute to the health and well-being of Canadians and we look forward to building a strong, positive presence in the Canadian healthcare sector."
"The opening of our Canadian operations is a very important milestone for Otsuka," said Mark Altmeyer, President and CEO of Otsuka America Pharmaceutical, Inc., parent company of OCPI. "As an organization, we are committed to expanding our presence around the world to ensure we are able to live our mission of creating new products for better health worldwide."
Russell Williams, President of Rx&D, Canada's Research-Based Pharmauceutical Companies, welcomed the arrival of OCPI: "As one of the world's leading pharmaceutical innovators and manufacturers, Otsuka's investment is excellent news for Canada. Patients across the country will benefit from their innovative medicines once introduced on the market. It also makes our research community and the life sciences sector stronger in the province of Quebec."
About Otsuka Pharmaceutical Co.,Ltd.
Founded in 1964, Otsuka Pharmaceutical Co.,Ltd. is a global healthcare company with the corporate philosophy 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases, and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. For more information, visit www.otsuka.co.jp/en .
About Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. (OAPI) is a successful, innovative, fast-growing healthcare company that commercializes Otsuka-discovered and other product opportunities in North America, with a strong focus on and commitment to neuroscience, cardiovascular, oncologic, and gastrointestinal therapeutic treatments. OAPI is dedicated to improving patients' health and the quality of human life. OAPI is part of the Otsuka Pharmaceutical Group, and was established in 1989 by Otsuka America, Inc. (OAI), which is wholly owned by Otsuka Pharmaceutical Co., Ltd. (OPC). For additional information, please visit www.otsuka-us.com.
About Bristol-Myers Squibb Canada
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb Canada is a leading provider of medicines to fight cancer, cardiovascular and metabolic disorders, infectious diseases (including HIV/AIDS), nervous system diseases and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMY symbol (NYSE:BMY). Bristol-Myers Squibb Canada's operations are headquartered in Montréal, Québec.
Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 18,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.
Information in this news release was current as of the original release date.